Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2015 Dec 7;7(12):6360-70.
doi: 10.3390/v7122943.

Emergent HIV-1 Drug Resistance Mutations Were Not Present at Low-Frequency at Baseline in Non-Nucleoside Reverse Transcriptase Inhibitor-Treated Subjects in the STaR Study

Danielle P Porter  1 , Martin Daeumer  2 , Alexander Thielen  3 , Silvia Chang  4 , Ross Martin  5 , Cal Cohen  6 , Michael D Miller  7 , Kirsten L White  8
Affiliations
Clinical Trial

Emergent HIV-1 Drug Resistance Mutations Were Not Present at Low-Frequency at Baseline in Non-Nucleoside Reverse Transcriptase Inhibitor-Treated Subjects in the STaR Study

Danielle P Porter et al. Viruses. .

Abstract

At Week 96 of the Single-Tablet Regimen (STaR) study, more treatment-naïve subjects that received rilpivirine/emtricitabine/tenofovir DF (RPV/FTC/TDF) developed resistance mutations compared to those treated with efavirenz (EFV)/FTC/TDF by population sequencing. Furthermore, more RPV/FTC/TDF-treated subjects with baseline HIV-1 RNA >100,000 copies/mL developed resistance compared to subjects with baseline HIV-1 RNA ≤100,000 copies/mL. Here, deep sequencing was utilized to assess the presence of pre-existing low-frequency variants in subjects with and without resistance development in the STaR study. Deep sequencing (Illumina MiSeq) was performed on baseline and virologic failure samples for all subjects analyzed for resistance by population sequencing during the clinical study (n = 33), as well as baseline samples from control subjects with virologic response (n = 118). Primary NRTI or NNRTI drug resistance mutations present at low frequency (≥2% to 20%) were detected in 6.6% of baseline samples by deep sequencing, all of which occurred in control subjects. Deep sequencing results were generally consistent with population sequencing but detected additional primary NNRTI and NRTI resistance mutations at virologic failure in seven samples. HIV-1 drug resistance mutations emerging while on RPV/FTC/TDF or EFV/FTC/TDF treatment were not present at low frequency at baseline in the STaR study.

Keywords: efavirenz; minority variants; resistance; rilpivirine; virologic failure.

PubMed Disclaimer

References

    1. Department for Health and Human Services (DHHS) Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents. Developed by the Dhhs Panel on Antiretroviral Guidelines for Adults and Adolescents—A Working Group of the Office of Aids Research Advisory Council (OARAC) [(accessed on 5 November 2015)]; Available online: http://aidsinfo.Nih.Gov/guidelines.
    1. Li J.Z., Paredes R., Ribaudo H.J., Kozal M.J., Svarovskaia E.S., Johnson J.A., Geretti A.M., Metzner K.J., Jakobsen M.R., Hullsiek K.H., et al. Impact of minority nonnucleoside reverse transcriptase inhibitor resistance mutations on resistance genotype after virologic failure. J. Infect. Dis. 2013;207:893–897. doi: 10.1093/infdis/jis925. - DOI - PMC - PubMed
    1. Nicot F., Saune K., Raymond S., Jeanne N., Carcenac R., Lefebvre C., Cuzin L., Marchou B., Delobel P., Izopet J. Minority resistant HIV-1 variants and the response to first-line NNRTI therapy. J. Clin. Virol. 2015;62:20–24. doi: 10.1016/j.jcv.2014.10.020. - DOI - PubMed
    1. Lataillade M., Chiarella J., Yang R., Schnittman S., Wirtz V., Uy J., Seekins D., Krystal M., Mancini M., McGrath D., et al. Prevalence and clinical significance of HIV drug resistance mutations by ultra-deep sequencing in antiretroviral-naive subjects in the CASTLE study. PLoS ONE. 2010;5:e10952. doi: 10.1371/journal.pone.0010952. - DOI - PMC - PubMed
    1. Messiaen P., Verhofstede C., Vandenbroucke I., Dinakis S., van Eygen V., Thys K., Winters B., Aerssens J., Vogelaers D., Stuyver L.J., et al. Ultra-deep sequencing of HIV-1 reverse transcriptase before start of an NNRTI-based regimen in treatment-naive patients. Virology. 2012;426:7–11. doi: 10.1016/j.virol.2012.01.002. - DOI - PubMed

Publication types

MeSH terms

LinkOut - more resources